Scalper1 News
Specialty generic drugmaker Insys Therapeutics (INSY) beat analysts’ Q4 estimates Tuesday, but it got only a short-lived boost on the stock market. Insys made 53 cents a share in the quarter, excluding one-time items, up 13% from the year-earlier quarter and beating analysts’ consensus by 9 cents. Revenue rose 65% to $66.5 million, about $2 million more than expected, according to Thomson Reuters. For the year, sales more than doubled to $222 Scalper1 News
Scalper1 News